Glenmark Pharmaceuticals reduces price of breast cancer drug Trastuzumab

15 Jun 2023 Evaluate

Glenmark Pharmaceuticals has slashed the price of breast cancer drug Trastuzumab by bringing its brand Trumab at Rs 15,749 for a 440 mg vial from Rs 54,000 earlier. Trastuzumab is used in the treatment of a particular type of breast cancer HER2-positive and the company markets its version in India under the brand name 'Trumab'.

This price reduction will bring the per mg cost of Trumab to around Rs 35, making it the most affordable treatment option for HER2-positive breast cancer in the country.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1178.00 17.25 (1.49%)
03-Jun-2024 14:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.90
Dr. Reddys Lab 5788.90
Cipla 1449.20
Zydus Lifesciences 1034.85
Lupin 1585.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.